Responses
Spondyloarthritis
Original article
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
Compose a Response to This Article
Other responses
No responses have been published for this article.